Beclomethasone dipropionate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1976
- First approval year
- 1976
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Beclomethasone dipropionate
- Molecular weight
- 521.05
- Structure (SMILES)
- CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
- aerobec 100
- Aerobec 100
- aerobec 50
- Aerobec 50
- aerobec fte 250
- Aerobec fte 250
- asmabec clickhaler
- Asmabec clickhaler
- asmabec spacehaler
- Asmabec spacehaler
- beclazone 100
- Beclazone 100
- beclazone 100 e breathe
- Beclazone 100 e-breathe
- beclazone 200
- Beclazone 200
- beclazone 250
- Beclazone 250
- beclazone 250 e breathe
- Beclazone 250 e-breathe
- beclazone 50
- Beclazone 50
- beclazone 50 e breathe
- Beclazone 50 e-breathe
- becloaqua 50
And 113 more, listed on the interactive page.
- 9 chloro 11β 17 21 trihydroxy 16β methylpregna 1 4 diene 3 20 dione 17 21 dipropionate
- 9-Chloro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
- BDP HFA Inhalation Aerosol (QVAR)
- bdp hfa inhalation aerosol qvar
- beclometasona
- Beclometasona
- beclometasone
- Beclometasone
- beclometasone dipropionate
- Beclometasone dipropionate
- BECLOMETASONE DIPROPIONATE [EP MONOGRAPH]
- BECLOMETASONE DIPROPIONATE [JAN]
- Beclometasone dipropionate [WHO-DD]
- BECLOMETASONE DIPROPIONATE [WHO-IP]
- beclometasone dipropionate anhydrous
- BECLOMETASONE DIPROPIONATE ANHYDROUS
- beclometasone dipropionate anhydrous ep impurity
- beclometasone dipropionate ep monograph
- beclometasone dipropionate jan
- beclometasone dipropionate who dd
- beclometasone dipropionate who ip
- BECLOMETASONE DIPROPIONATE, ANHYDROUS
- BECLOMETASONE DIPROPIONATE, ANHYDROUS [EP IMPURITY]
- BECLOMETASONI DIPROPIONAS [WHO-IP LATIN]
- beclometasoni dipropionas who ip latin
And 78 more, listed on the interactive page.
- CAS registry numbers
- 5534-09-8
- ChEMBL ID
- CHEMBL1200500
- InChIKey
- KUVIULQEHSCUHY-XYWKZLDCSA-N
- PubChem compound IDs
- 21700
- FDA ingredient codes (UNII)
- 5B307S63B2
- A07EA07
- D07AC15
- R01AD01
- R03BA01
Sources for recorded values
- 1347
- 1348
- Applicant
- TEVA BRANDED PHARM
- Approval date
- 23 Mar 2012
- Application number
- NDA202813
- Status
- application_withdrawn
- Status date
- 22 May 2008
- Product number
- EMEA/H/C/000803
- Authorisation holder
- DOR BIOPHARMA UK Ltd
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Graft vs Host Disease
European medicines record
- Patents
- 23
- Designations
- 1
- Earliest recorded loss of exclusivity
- 19 Aug 2041
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- Yes
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- beclometasone dipropionate
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- ADGRG3
- Gene symbol
- ADGRG3
- Protein identifier
- Q86Y34
- Median affinity
- 8.5
- Affinity units
- pEC50
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Agonist
- Gene symbol
- ADGRG3
- Protein identifier
- Q86Y34
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003956
- Subject identifier
- D006255
- Condition
- Eosinophilic Esophagitis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004232
- Subject identifier
- D057765
- Condition
- Graft vs Host Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004599
- Subject identifier
- D006086
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005854
- Subject identifier
- D006255
- Condition
- Rhinitis, Allergic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005854
- Subject identifier
- D065631
- Condition
- Croup
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007227
- Subject identifier
- D003440
- Condition
- Sinusitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007486
- Subject identifier
- D012852
- Condition
- Nasal Polyps
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000391
- Subject identifier
- D009298
- Condition
- Respiratory Distress Syndrome, Newborn
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000644
- Subject identifier
- D012127
- Condition
- Folliculitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000702
- Subject identifier
- D005499
- Condition
- Rhinitis, Allergic, Perennial
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001417
- Subject identifier
- D012221
- Condition
- Nasal Obstruction
- Highest recorded phase
- 4
- Condition identifier
- HP:0001742
- Subject identifier
- D015508
- Condition
- Bronchiectasis
- Highest recorded phase
- 3
- Condition identifier
- HP:0002110
- Subject identifier
- D001987
- Condition
- Lung Diseases, Obstructive
- Highest recorded phase
- 4
- Condition identifier
- HP:0006536
- Subject identifier
- D008173
- Condition
- Asthma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Graft vs Host Disease
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0013730
- Subject identifier
- D006086
- Condition
- Bronchopulmonary Dysplasia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0019091
- Subject identifier
- D001997
- Condition
- Bronchiolitis Obliterans Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0020547
- Subject identifier
- D000092122
- Condition
- Enteritis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0043579
- Subject identifier
- D004751
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0000384
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003956
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004232
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004318
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004599
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005854
- Condition identifier
- EFO_0007227
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007486
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000391
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000702
- Condition identifier
- EFO_1001417
- Condition identifier
- HP_0001742
- Condition identifier
- HP_0001742
- Highest recorded phase
- 4
- Condition identifier
- HP_0002094
- Condition identifier
- HP_0006536
- Condition identifier
- HP_0006536
- Highest recorded phase
- 4
- Condition identifier
- HP_0012735
- Condition identifier
- HP_0030828
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002465
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004822
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004979
And 16 more, listed on the interactive page.
- Event
- acquired macroglossia
- Reports
- 6
- Reporting signal score
- 28.8972
- Event
- angioplasty
- Reports
- 8
- Reporting signal score
- 23.3295
- Event
- anosmia
- Reports
- 18
- Reporting signal score
- 41.6749
- Event
- asthma
- Reports
- 315
- Reporting signal score
- 882.514
- Event
- atelectasis
- Reports
- 15
- Reporting signal score
- 24.2455
- Event
- bacterial disease carrier
- Reports
- 8
- Reporting signal score
- 29.9823
- Event
- beta haemolytic streptococcal infection
- Reports
- 16
- Reporting signal score
- 58.7145
- Event
- blood count abnormal
- Reports
- 25
- Reporting signal score
- 40.6703
- Event
- breast conserving surgery
- Reports
- 10
- Reporting signal score
- 45.1205
- Event
- bronchial secretion retention
- Reports
- 9
- Reporting signal score
- 32.4138
- Event
- candida pneumonia
- Reports
- 7
- Reporting signal score
- 32.0062
- Event
- central obesity
- Reports
- 10
- Reporting signal score
- 37.1725
- Event
- chest discomfort
- Reports
- 42
- Reporting signal score
- 29.4408
- Event
- choking
- Reports
- 13
- Reporting signal score
- 21.3957
- Event
- chorioretinopathy
- Reports
- 10
- Reporting signal score
- 24.7718
- Event
- cough
- Reports
- 109
- Reporting signal score
- 83.3129
- Event
- crepitations
- Reports
- 21
- Reporting signal score
- 64.1952
- Event
- cushing's syndrome
- Reports
- 15
- Reporting signal score
- 32.7354
- Event
- device delivery system issue
- Reports
- 8
- Reporting signal score
- 22.2803
- Event
- drug hypersensitivity
- Reports
- 101
- Reporting signal score
- 56.3583
- Event
- dysbiosis
- Reports
- 6
- Reporting signal score
- 24.0166
- Event
- dyspnoea
- Reports
- 187
- Reporting signal score
- 108.638
- Event
- eosinophilia
- Reports
- 22
- Reporting signal score
- 26.7998
- Event
- epistaxis
- Reports
- 33
- Reporting signal score
- 23.3559
- Event
- fatigue
- Reports
- 20
- Reporting signal score
- 21.2501
And 31 more, listed on the interactive page.
- NCT00000576
- NCT01373008
- NCT00000578
- NCT00094016
- NCT00109668
- NCT00119496
- NCT00200967
- NCT00382889
- NCT00394329
- NCT00394368
- NCT00395408
- NCT00413387
- NCT00497237
- NCT00497523
- NCT00565266
- NCT00862264
- NCT00862394
- NCT00868023
- NCT00901368
- NCT00910793
- NCT00911547
- NCT01006655
- NCT01255579
- NCT01333800
- NCT01345916
And 59 more, listed on the interactive page.
- Dose
- 40 mcg, 80 mcg, 160 mcg, or 320 mcg
- Route
- Inhalation
- How often
- Twice daily
- Discard when dose counter displays 0 or after expiration date
- Prime before first use or if not used for over 10 days
- Use with spacer device in children 5 years or older is not recommended
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 106.97
- Calculated partition coefficient (ALogP)
- 4.09
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 6
- Heavy atoms
- 36
- Molecular formula
- C28H37ClO7
- Monoisotopic mass
- 520.2227812
- Natural product
- Yes
- 10122-120
- 10122-121
- 10122-460
- 10122-590
- 59310-302
- 59310-304
- 59310-406
- 59310-410
- 50090-3458
- 50090-3459
- 50090-5031
- 50090-5032
- 69238-1289
- 69238-1290
- Recorded assays
- 2,684
- Active assays
- 35
- Confirmatory
- Other
- Screening
- Summary
- Anti-Asthmatic Agents
Drugs that are used to treat asthma.
- Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION.
- Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Related records
Trials (199)
- (CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)
- 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
- A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
- A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV
- A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
- A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
- A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
- A Study Comparing the Effects of Trimbow to Fostair in COPD
- A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
- A Study in Patients With Chronic Obstructive Pulmonary Disease
- A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
- A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
- A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler
- A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers
Approved for (5)
- Allergic rhinitis
- Asthma
- Obstructive lung disease
- Perennial allergic rhinitis
- Seasonal allergic rhinitis
In development for (16)
- Bronchiectasis Phase 3
- Bronchopulmonary dysplasia Phase 3
- Chronic graft versus host disease Phase 2
- Chronic obstructive pulmonary disease Phase 3
- COVID-19 Phase 2
- Crohn disease Phase 2
- Croup Phase 3
- Enteritis Phase 1
- Eosinophilic esophagitis Phase 1
- Folliculitis Phase 2
- Graft versus host disease Phase 3
- Idiopathic pulmonary fibrosis Phase 2
- Nasal cavity polyp Phase 2
- Newborn respiratory distress syndrome Phase 3
- Sinusitis Phase 3
- Small cell lung carcinoma Phase 2
Targets (1)
- NR3C1 Glucocorticoid receptor agonist